The next generation of PPAR drugs: Do we have the tools to find them?

Agonists of PPARα and PPARγ are currently approved for use in treating, respectively, dyslipidemia and type 2 diabetes. Agonists of PPARβ/δ are currently in development by several pharmaceutical companies. Despite their therapeutic importance, there are dose limiting side effects associated with PPA...

Full description

Saved in:
Bibliographic Details
Published inBiochimica et biophysica acta Vol. 1771; no. 8; pp. 1082 - 1093
Main Authors Shearer, Barry G., Billin, Andrew N.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.08.2007
Subjects
Diabetes Mellitus, Type 2 - drug therapy
Drug Design
Drug discovery
Dyslipidemias - drug therapy
Humans
Hypoglycemic Agents - therapeutic use
Hypolipidemic Agents - therapeutic use
Peroxisome Proliferator-Activated Receptors - agonists
PPAR
PPAR alpha - agonists
PPAR gamma - agonists
Safety
TZD
Safety
Drug discovery
PPAR
TZD
Online AccessGet full text

Cover

More Information
Summary:Agonists of PPARα and PPARγ are currently approved for use in treating, respectively, dyslipidemia and type 2 diabetes. Agonists of PPARβ/δ are currently in development by several pharmaceutical companies. Despite their therapeutic importance, there are dose limiting side effects associated with PPAR drug treatments, thus a new generation of safer PPAR drugs are being actively sought after. In this review we will discuss the side effects associated the PPARs, how the current drugs in clinical development were discovered and new concepts in how to screen for PPAR drugs.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1388-1981
0006-3002
1879-2618
DOI:10.1016/j.bbalip.2007.05.005